A double blind, randomized, placebo controlled study to evaluate the efficacy of erythromycin in patients with knee effusion due to osteoarthritis

International Journal of Rheumatic Diseases

Volumn 12, Issue 1, 2009, Pages 44-51

  Sadreddini, Shahram ^a   Noshad, Hamid ^a   Molaeefard, Mahshid ^a   Moloudi, Ramona ^b   Ardalan, Mohamad Reza ^b   Ghojazadeh, Morteza ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE

Author keywords

Erythromycin; Knee effusion; Osteoarthritis

Indexed keywords

ERYTHROMYCIN; PARACETAMOL; PLACEBO;

ADULT; AGED; ANALGESIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; JOINT EFFUSION; JOINT FUNCTION; JOINT STIFFNESS; KNEE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

ACETAMINOPHEN; ADULT; AGED; ANALGESICS, NON-NARCOTIC; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ERYTHROMYCIN; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; RANGE OF MOTION, ARTICULAR; TREATMENT OUTCOME;

EID: 63849175474     PISSN: 17561841     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2009.01379.x     Document Type: Article

References (42)

1. Creamer P, Hochberg MC (1997) Osteoarthritis. Lancet 350, 503-8.
2. O'Dell JR, Paulsen G, Haire CE (1999) Treatment of early seropositive rheumatoid arthritis with minocycline: Four-year follows up of a double blind, placebo-controlled trial. Arth Rheum 42, 1691-5.
3. Marshall SE (2004) Behçet's disease. Best Prac Res Clin Rheum 18, 291-311.
4. 2 production. J Immunol 163, 3459-67.
5. Menninger JR, Otto DP (1982) Erythromycin, carbomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes. Antimicrob Agents Chemother 21, 811-8.
6. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M (1998) Improvement of Survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 157, 1829-32.
7. Culic O, Erakovic V, Parnham MJ (2001) Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 429, 209-29.
8. Takeshita K, Yamagishi I, Harada M, Otomo S, Nakagawa T, Mizushima Y (1989) Immunological and anti-inflammatory effects of clarithromycin: Inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp Clin Res 15, 527-33.
9. Hand WL, Hand DL, King-Thompson NL (1990) Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob Agents Chem 34, 863-70.
10. Mikasa K, Kita E, Sawaki M, et al. (1992) The anti-inflammatory effect of erythromycin in zymosan-induced peritonitis of mice. J Antimicrob Chemother 30, 339-48.
11. Konno S, Asano K, Kurokawa M, Ikeda K, Okamoto K, Adachi M (1994) Antiasthmatic activity of a macrolide antibiotic, roxithromycin: Analysis of possible mechanisms in vitro and in vivo. Int Arch Allergy Immunol 105, 308-16.
12. Laufen H, Wildfeuer A, Räder K (1985) Uptake of antimicrobial agents by human polymorphonuclear leucocytes. Arzneimittelforschung 35, 1097-9.
13. Labro MT, Abdelghaffar H (2001) Immunomodulation by macrolide antibiotics. J Chemother 13, 3-8.
14. Altman R, Asch E, Bloch G, et al. (1986) Development of criteria for the classification and reporting of osteoarthritis. Arthritis Rheum 29, 1039-49.
15. Nijs J, Van Geel C, Van der auwera C, Van de Velde B (2006) Diagnostic value of five clinical tests in patellofemoral pain syndrome. Man Ther 11, 69-77.
16. Bellamy N, Buchanan WW, Goldsmith CH, Campblel J, Stitt LW (1988) Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15, 1833-40.
17. Gajdosik RL, Bohannon RW (1987) Clinical measurement of range of motion; Review of goniometry emphasizing reliability and validity. Phys Therap 67, 1867-72.
18. Eadie WT, Drijard D, James FE, Roos M, Sadoulet B (1971) Statistical Methods in Experimental Physics, pp. 269-71. North-Holland, Amsterdam.
19. Felson DT, McAlindon TE, Anderson JJ, et al. (1997) Defining radiographic osteoarthritis for the whole knee. Osteoarth Cartil 5, 241-50.
20. Brandt KD, Doberty M, Lobmander S, et al. (1998) Osteoarthritis. Oxford University Press, New York.
21. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M (1997) Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 24, 365-71.
22. Bjordal JM, Ljunggren AE, Klovning A (2004) Non-steroidal anti-inflammatory drugs, including coxibs, in osteoarthritic knee pain: a meta-analysis of randomized placebo-controlled trials. BMJ 329, 1317-20.
23. British Medical Association, Royal Pharmaceutical Society of Great Britain (2004) British National Formulary. BMA, RPS, London. (No 48).
24. Brandt KD, Bradley JD (2001) Should the initial drug used to treat osteoarthritis pain be a nonsteroidal anti-inflammatory drug? J Rheumatol 28, 467-73.
25. Gossec L, Dougados M (2004) Intra-articular treatments in osteoarthritis: From the symptomatic to the structure modifying. Ann Rheum Dis 63, 478-82.
26. Charalambous Cp, Tryfonidis M, Sadiq S (2003) Septic arthritis following intra-articular steroid injection of the knee. Clin Rheumtol 22, 386-90.
27. Reuven M, Idit L, Rafael L (2005) Evaluation of the pituitary-adrenal axis function following single intraarticular injection of methylprednisolone. Arthritis Rheum 52, 924-8.
28. Reid DM, Patel S, Reid IW (1983) Hypothalamic-pituitary-adrenal (HPA) axis function in patients receiving long-term intra-articular corticosteroids. Clinic Rheumatol 2, 159-61.
29. Emkey RD, Lindsay R, Lyssy J, Weisberg J, Dempster D, Shen V (1996) The systemic effect of intra-articular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum 39, 277-82.
30. Bryskier A, Agouridas C, Chantot JF (1994) New medical targets for macrolides. Exp Opin Invest Drugs 3, 405-10.
31. Zhao DM, Xue HH, Chida K, et al. (2000) Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells. Am J Physiol Lung Cell Mol Physiol 278, 726-36.
32. Idesaki M, Okazaki H, Takizawa H (2001) Effect of 14-membered ring macrolide on transcription factors in human bronchial epithelial cells. Jpn J Antibiotics 54, 43-5.
33. Lechapt-Zalcman E, Coste A, Pia d'Ortho M, et al. (2001) Increased expression of matrix metalloproteinase-9 in nasal polyps. J Pathol 193, 233-41.
34. Cawston T (1998) Matrix metalloproteinases and TIMPs: Properties and implications for the rheumatic diseases. Mol Med Today 4, 130-7.
35. Kadota J, Matsubara Y, Ishimatsu Y, et al. (1996) Significance of IL-1 and IL-1 receptor antagonist (IL-1Ra) in bronchoalveolar lavage fluid (BALF) in patients with diffuse parabronchiolitis (DPB). Clin Exp Immunol 103, 461-6.
36. Lazaar AL, Amrani Y, Hsu J, et al. (1998) CD40-mediated signal transduction in human airway smooth muscle. J Immunol 161, 3120-7.
37. Weiping R, Xiao HL, Ben DC, Wooley PH (2003) Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-B activity. J Orthop Res 22, 21-9.
38. Ianaro A, Ialenti A, Maffia P, et al. (2000) Anti-Inflammatory Activity of Macrolide Antibiotics. Pharma Exp Therap 292, 156-63.
39. Lotz M (1999) The role of nitric oxide in articular cartilage damage. Rheum Dis Clin North Am 25, 269-82.
40. Tamaoki J (2004) The effects of macrolides on inflammatory cells. Chest 125, 41S-51S.
41. Marcus JS (2004) Macrolide activities beyond their antimicrobial effects: Macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemoth 54, 21-8.
42. Lehmann R, Brzosko M, Kopsa P, et al. (2005) Efficacy and tolerability of lumiracoxib 100.mg once daily in knee osteoarthritis: A 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin 21, 517-26.